{"entity":{"id":"nct03150693","kind":"trial","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","aka":[],"tldr":"A phase 3 trial of Cytarabine, Daunorubicin, Vincristine, Dexamethasone, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine and Inotuzumab ozogamicin in Acute lymphoblastic leukaemia, run by Alliance for Clinical Trials in Oncology, now recruiting.","summary":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia is a phase 3 interventional study registered as NCT03150693 by Alliance for Clinical Trials in Oncology, with 303 participants planned, started 2017-09-20 and due to reach its primary completion in 2027-03-01. Interventions recorded: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis. Conditions recorded: B Acute Lymphoblastic Leukemia.\n\nLinked to the drug Mercaptopurine because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03150693","url":"https://clinicaltrials.gov/study/NCT03150693"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["cytarabine","daunorubicin","vincristine","dexamethasone","methotrexate","cyclophosphamide","mercaptopurine","rituximab","doxorubicin","thioguanine","inotuzumab-ozogamicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03150693","phase":"3","setting":"A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL","sponsor":"Alliance for Clinical Trials in Oncology","enrolled":303,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03150693/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/"},{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/"},{"id":"mercaptopurine","kind":"drug","name":"Mercaptopurine","route":"/drugs/mercaptopurine/"},{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"thioguanine","kind":"drug","name":"Thioguanine","route":"/drugs/thioguanine/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}]}}